$ETNB
89bio, Inc.

2023 Q1 Form 10-K Financial Statement

#000095017023007929 Filed on March 15, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.218M $6.298M $21.45M
YoY Change 18.24% 19.69% 10.51%
% of Gross Profit
Research & Development $22.31M $19.06M $80.80M
YoY Change 12.38% -9.13% 14.88%
% of Gross Profit
Depreciation & Amortization $14.00K $15.00K $65.00K
YoY Change -22.22% -28.57% -17.72%
% of Gross Profit
Operating Expenses $28.52M $25.36M $102.2M
YoY Change 43.7% -3.35% 13.94%
Operating Profit -$28.52M -$102.2M
YoY Change 13.61% 13.94%
Interest Expense $2.075M $1.922M
YoY Change 408.58% -580.5%
% of Operating Profit
Other Income/Expense, Net $1.763M $776.0K $2.164M
YoY Change -486.62% -500.0% -511.41%
Pretax Income -$28.84M -$24.59M -$102.0M
YoY Change 12.8% -6.99% 13.0%
Income Tax $0.00 $16.00K $19.00K
% Of Pretax Income
Net Earnings -$28.84M -$24.60M -$102.0M
YoY Change 12.79% -6.41% 13.21%
Net Earnings / Revenue
Basic Earnings Per Share -$0.54 -$2.93
Diluted Earnings Per Share -$0.54 -$0.48 -$2.93
COMMON SHARES
Basic Shares Outstanding 52.23M 46.54M 34.81M
Diluted Shares Outstanding 53.17M 34.81M

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $480.9M $188.2M $188.2M
YoY Change 281.39% 24.84% 24.84%
Cash & Equivalents $350.9M $55.26M $55.26M
Short-Term Investments $130.0M $132.9M $132.9M
Other Short-Term Assets $12.75M $7.920M $7.920M
YoY Change 36.73% -29.68% -29.68%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $493.6M $196.1M $196.1M
YoY Change 264.55% 21.05% 21.05%
LONG-TERM ASSETS
Property, Plant & Equipment $78.00K $92.00K $455.0K
YoY Change -43.48% -38.67% 203.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $289.0K $289.0K $289.0K
YoY Change 32.57% -0.34% -0.34%
Total Long-Term Assets $689.0K $744.0K $744.0K
YoY Change 93.54% 69.09% 69.09%
TOTAL ASSETS
Total Short-Term Assets $493.6M $196.1M $196.1M
Total Long-Term Assets $689.0K $744.0K $744.0K
Total Assets $494.3M $196.8M $196.8M
YoY Change 264.1% 21.18% 21.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $16.73M $12.50M $12.50M
YoY Change 278.35% 82.7% 82.7%
Accrued Expenses $7.117M $11.94M $12.11M
YoY Change -20.74% 17.17% 18.81%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00
YoY Change -100.0% -100.0%
Total Short-Term Liabilities $24.02M $24.61M $24.61M
YoY Change 30.52% 25.99% 25.99%
LONG-TERM LIABILITIES
Long-Term Debt $24.33M $19.69M $19.69M
YoY Change 68.12% 16.53% 16.53%
Other Long-Term Liabilities $142.0K $687.0K $687.0K
YoY Change -5.96% 2190.0% 2190.0%
Total Long-Term Liabilities $24.33M $19.69M $20.38M
YoY Change 68.12% 16.53% 20.38%
TOTAL LIABILITIES
Total Short-Term Liabilities $24.02M $24.61M $24.61M
Total Long-Term Liabilities $24.33M $19.69M $20.38M
Total Liabilities $48.49M $44.99M $44.99M
YoY Change 46.83% 23.38% 23.38%
SHAREHOLDERS EQUITY
Retained Earnings -$344.1M -$315.2M
YoY Change 44.1% 47.85%
Common Stock $790.1M $467.4M
YoY Change 131.19% 37.79%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $445.8M $151.8M $151.8M
YoY Change
Total Liabilities & Shareholders Equity $494.3M $196.8M $196.8M
YoY Change 264.1% 21.18% 21.18%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$28.84M -$24.60M -$102.0M
YoY Change 12.79% -6.41% 13.21%
Depreciation, Depletion And Amortization $14.00K $15.00K $65.00K
YoY Change -22.22% -28.57% -17.72%
Cash From Operating Activities -$30.09M -$27.10M -$81.09M
YoY Change 23.58% -4.05% 5.61%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $2.000K $7.000K
YoY Change -100.0% -107.41% -88.89%
Acquisitions
YoY Change
Other Investing Activities $4.106M -$11.06M -$33.94M
YoY Change -84.67% -157.86% -569.9%
Cash From Investing Activities $4.106M -$11.06M -$33.94M
YoY Change -84.66% -157.95% -574.13%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $50.00K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 321.7M 21.01M 117.8M
YoY Change 1109051.72% -4.02% 393.62%
NET CHANGE
Cash From Operating Activities -30.09M -27.10M -81.09M
Cash From Investing Activities 4.106M -11.06M -33.94M
Cash From Financing Activities 321.7M 21.01M 117.8M
Net Change In Cash 295.7M -17.15M 2.798M
YoY Change 11933.98% -234.62% -106.12%
FREE CASH FLOW
Cash From Operating Activities -$30.09M -$27.10M -$81.09M
Capital Expenditures $0.00 $2.000K $7.000K
Free Cash Flow -$30.09M -$27.10M -$81.10M
YoY Change 23.55% -3.95% 5.53%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001785173
CY2022 us-gaap Variable Lease Payment
VariableLeasePayment
0
CY2022 us-gaap Short Term Lease Cost
ShortTermLeaseCost
0
CY2022 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2019-06-30
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-39122
CY2022 dei Entity Registrant Name
EntityRegistrantName
89bio, Inc.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
36-4946844
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
142 Sansome Street
CY2022 dei Entity Address Address Line2
EntityAddressAddressLine2
Second Floor
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
San Francisco
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94104
CY2022 dei City Area Code
CityAreaCode
415
CY2022 dei Local Phone Number
LocalPhoneNumber
432-9270
CY2022 dei Security12b Title
Security12bTitle
Common stock, par value $0.001 per share
CY2022 dei Trading Symbol
TradingSymbol
ETNB
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022 dei Auditor Firm
AuditorFirmId
185
CY2022 dei Auditor Name
AuditorName
KPMG LLP
CY2022 dei Auditor Location
AuditorLocation
San Francisco, California, USA
CY2022Q2 dei Entity Public Float
EntityPublicFloat
30400000
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
52230621
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20317204
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
51000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
20000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
467374000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
55255000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
52432000
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
25000
CY2022Q4 etnb Short Term Available For Sale Securities Current
ShortTermAvailableForSaleSecuritiesCurrent
132905000
CY2021Q4 etnb Short Term Available For Sale Securities Current
ShortTermAvailableForSaleSecuritiesCurrent
98288000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7920000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11237000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
196080000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
161982000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
363000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
92000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
150000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
289000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
290000
CY2022Q4 us-gaap Assets
Assets
196824000
CY2021Q4 us-gaap Assets
Assets
162422000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
12502000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6843000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11944000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10194000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
168000
CY2021Q4 etnb Term Loan Current
TermLoanCurrent
2500000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
24614000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
19537000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
186000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
19691000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
16898000
CY2022Q4 etnb Other Non Current Liability
OtherNonCurrentLiability
501000
CY2021Q4 etnb Other Non Current Liability
OtherNonCurrentLiability
30000
CY2022Q4 us-gaap Liabilities
Liabilities
44992000
CY2021Q4 us-gaap Liabilities
Liabilities
36465000
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
50560590
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
50560590
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20317204
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
339218000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-350000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-64000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-315243000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-213217000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
151832000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
125957000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
196824000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
162422000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
80796000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
70330000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
21453000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19413000
CY2022 us-gaap Operating Expenses
OperatingExpenses
102249000
CY2021 us-gaap Operating Expenses
OperatingExpenses
89743000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-102249000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-89743000
CY2022 us-gaap Interest Expense
InterestExpense
1922000
CY2021 us-gaap Interest Expense
InterestExpense
674000
CY2022 us-gaap Interest And Other Income
InterestAndOtherIncome
2164000
CY2021 us-gaap Interest And Other Income
InterestAndOtherIncome
148000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-102007000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-90269000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
19000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-147000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-102026000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-90122000
CY2022 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-299000
CY2021 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-71000
CY2022 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
13000
CY2021 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
17000
CY2022 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-286000
CY2021 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-54000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-102312000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-90176000
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.93
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.93
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.48
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.48
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34806349
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34806349
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20098340
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20098340
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
202961000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
487000
CY2021 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
144000
CY2021 etnb Issuance Of Common Stock Warrant In Connection With Term Loan Facility
IssuanceOfCommonStockWarrantInConnectionWithTermLoanFacility
574000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8678000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-90122000
CY2021 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-54000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
125957000
CY2022 etnb Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
1082000
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
305000
CY2022 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
50000
CY2022 etnb Stock Issued During Period Value Restricted Stock Award Net Of Withholding Taxes
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfWithholdingTaxes
-298000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10356000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-102026000
CY2022 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-286000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
151832000
CY2022 us-gaap Profit Loss
ProfitLoss
-102026000
CY2021 us-gaap Profit Loss
ProfitLoss
-90122000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
10356000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
8678000
CY2022 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
980000
CY2021 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-865000
CY2022 etnb Amortization Of Debt Issuance Costs And Accretion Of Final Payment Fee
AmortizationOfDebtIssuanceCostsAndAccretionOfFinalPaymentFee
-764000
CY2021 etnb Amortization Of Debt Issuance Costs And Accretion Of Final Payment Fee
AmortizationOfDebtIssuanceCostsAndAccretionOfFinalPaymentFee
-617000
CY2022 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
175000
CY2022 us-gaap Depreciation
Depreciation
65000
CY2021 us-gaap Depreciation
Depreciation
79000
CY2022 etnb Deferred Tax Assets
DeferredTaxAssets
0
CY2021 etnb Deferred Tax Assets
DeferredTaxAssets
150000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3331000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
5672000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
5659000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4778000
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1750000
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
4146000
CY2022 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-184000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-81090000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-76781000
CY2022 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
118760000
CY2021 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
148422000
CY2022 etnb Payment For Purchase Of Available For Sale Securities
PaymentForPurchaseOfAvailableForSaleSecurities
152696000
CY2021 etnb Payment For Purchase Of Available For Sale Securities
PaymentForPurchaseOfAvailableForSaleSecurities
141200000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
63000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-33943000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
7159000
CY2022 etnb Proceeds From Issuance Public Offering
ProceedsFromIssuancePublicOffering
88239000
CY2022 etnb Proceeds From Issuance Public Offering At The Market Offering
ProceedsFromIssuancePublicOfferingAtTheMarketOffering
28453000
CY2021 etnb Proceeds From Issuance Public Offering At The Market Offering
ProceedsFromIssuancePublicOfferingAtTheMarketOffering
3289000
CY2022 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1082000
CY2022 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
305000
CY2021 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
487000
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
50000
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
144000
CY2022 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
298000
CY2021 us-gaap Proceeds From Issuance Of Other Long Term Debt
ProceedsFromIssuanceOfOtherLongTermDebt
19951000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
117831000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
23871000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2798000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-45751000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
52457000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
98208000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
55255000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
52457000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
55255000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
52432000
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
0
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
25000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
55255000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
52457000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
1076000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
16000
CY2022 us-gaap Operating Lease Payments Use
OperatingLeasePaymentsUse
234000
CY2022 etnb Remeasurement Of Lease Liability And Right Of Use Asset In Connection With Lease Modification
RemeasurementOfLeaseLiabilityAndRightOfUseAssetInConnectionWithLeaseModification
338000
CY2021 etnb Issuance Of Common Stock Warrant In Connection With Term Loan Facility
IssuanceOfCommonStockWarrantInConnectionWithTermLoanFacility
574000
CY2022Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
188200000
CY2022 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Reclassification</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain prior year amounts in the Company’s consolidated statements of operations and comprehensive loss have been reclassified to conform to the current year presentation. Specifically, interest expense is disclosed separately on the Company’s consolidated statements of operations and comprehensive loss, which had no impact on reported net loss, comprehensive loss, or loss per share.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying consolidated financial statements include but are not limited to accrued research and development expenses and to the fair value of stock options. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.</span></p>
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents and short-term available-for-sale securities. Bank deposits are held by accredited financial institutions and these deposits may at times be in excess of insured limits. The Company limits its credit risk associated with cash and cash equivalents by placing them with financial institutions that it believes are of high quality. The Company has not experienced any losses on its deposits of cash or cash equivalents. The Company </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">limits amounts invested in available-for-sale securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. The Company is not exposed to any significant concentrations of credit risk from these financial instruments.</span></p>
CY2022 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022 us-gaap Other Than Temporary Impairment Loss Debt Securities Portion Recognized In Earnings
OtherThanTemporaryImpairmentLossDebtSecuritiesPortionRecognizedInEarnings
0
CY2022 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
175243000
CY2022Q4 etnb Available For Sale Securities Debt Maturities After One Through Two Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue
6202000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
181445000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
120726000
CY2021Q4 etnb Available For Sale Securities Debt Maturities After One Through Two Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue
5277000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
126003000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
4328000
CY2022Q4 etnb Prepaid Research And Development Current
PrepaidResearchAndDevelopmentCurrent
5727000
CY2021Q4 etnb Prepaid Research And Development Current
PrepaidResearchAndDevelopmentCurrent
7895000
CY2022Q4 us-gaap Prepaid Taxes
PrepaidTaxes
646000
CY2021Q4 us-gaap Prepaid Taxes
PrepaidTaxes
836000
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
1547000
CY2021Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
2506000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7920000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11237000
CY2022Q4 etnb Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
6499000
CY2021Q4 etnb Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
6195000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4165000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3168000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1052000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
495000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
228000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
336000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11944000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10194000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
300000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
300000
CY2022 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
200000
CY2022Q4 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P2Y
CY2022Q4 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.065
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.910
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.869
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.919
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.016
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.039
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.007
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.013
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
185000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
185000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
7000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
377000
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
23000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
354000
CY2021 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
300000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
212000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
7000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
219000
CY2022 etnb Percentage Of Fee On Loan
PercentageOfFeeOnLoan
0.050
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
14937136
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
13966283
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.899
CY2021Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
6529000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10356000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8678000
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.21
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.21
CY2022 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
-3000
CY2021 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
2000
CY2022 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
-16000
CY2021 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
1000
CY2022 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-19000
CY2021 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
3000
CY2021 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-150000
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-150000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
19000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-147000
CY2022Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
18927000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1969000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
317000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
220000
CY2022Q4 etnb Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
98000
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
244000
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
191000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
76301000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
42265000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
75982000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
42046000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
319000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
219000
CY2022Q4 etnb Deferred Tax Liabilities Rights Of Use Assets
DeferredTaxLiabilitiesRightsOfUseAssets
100000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
100000
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
219000
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
219000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
76000000.0
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
42000000.0
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
34000000.0
CY2022 us-gaap Operating Loss Carryforwards Limitations On Use
OperatingLossCarryforwardsLimitationsOnUse
Federal net operating losses generated after 2017 can be carried forward indefinitely but utilization will be limited to 80% of taxable income in the period that net operating losses are being utilized.
CY2022Q4 etnb Taxable Income Utilization Percentage
TaxableIncomeUtilizationPercentage
0.80
CY2022Q4 etnb Deferred Tax Assets Tax Credit Carryforwards Research Federal
DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal
4300000
CY2021Q4 etnb Deferred Tax Assets Tax Credit Carryforwards Research Federal
DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal
2100000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1800000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1100000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-102007000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-90269000
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
21429000
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
18757000
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-33936000
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-20111000
CY2022 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
1000
CY2021 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-19000
CY2022 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
5824000
CY2022 etnb Effective Income Tax Rate Reconciliation State Deferred Tax True Up Due To Change In Apportionment
EffectiveIncomeTaxRateReconciliationStateDeferredTaxTrueUpDueToChangeInApportionment
6517000
CY2021 etnb Income Tax Reconciliation Change In Effective Tax Rate Due To Reorganization
IncomeTaxReconciliationChangeInEffectiveTaxRateDueToReorganization
-2000
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense Research And Development
IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
2130000
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense Research And Development
IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
1331000
CY2022 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-1984000
CY2021 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
191000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
19000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-147000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
851000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
329000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
19000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
35000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
752000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
557000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1584000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
851000
CY2022 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
700000
CY2021 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
500000
CY2022Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17423938
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2571985

Files In Submission

Name View Source Status
etnb-20221231_cal.xml Edgar Link unprocessable
etnb-20221231_lab.xml Edgar Link unprocessable
0000950170-23-007929-index-headers.html Edgar Link pending
0000950170-23-007929-index.html Edgar Link pending
0000950170-23-007929.txt Edgar Link pending
0000950170-23-007929-xbrl.zip Edgar Link pending
etnb-20221231.htm Edgar Link pending
etnb-20221231.xsd Edgar Link pending
etnb-ex23_1.htm Edgar Link pending
etnb-ex31_1.htm Edgar Link pending
etnb-ex31_2.htm Edgar Link pending
etnb-ex32_1.htm Edgar Link pending
etnb-ex4_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img32108071_0.jpg Edgar Link pending
img32108071_1.jpg Edgar Link pending
img32108071_2.jpg Edgar Link pending
img32108071_3.jpg Edgar Link pending
img32108071_4.jpg Edgar Link pending
img32108071_5.jpg Edgar Link pending
img32108071_6.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
etnb-20221231_def.xml Edgar Link unprocessable
etnb-20221231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
etnb-20221231_htm.xml Edgar Link completed
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending